Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced that argenx has identified four new targets under their global collaboration and license agreement. This agreement grants argenx exclusive access to Halozyme’s ENHANZE® drug delivery technology, which utilizes the proprietary recombinant human hyaluronidase…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) has announced the conclusion of a sales partnership agreement with Nxera Pharma Japan Co., Ltd. (hereafter “Nxera Pharma Japan”), a subsidiary of Nxera Pharma Co., Ltd.…
Gilead Sciences, Inc. (Nasdaq: GILD) has announced the signing of non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to produce and distribute generic lenacapavir in 120 high-incidence, resource-limited countries, primarily targeting low- and lower-middle-income regions. These agreements precede any…
PharmaJet®, a leader in enhancing the efficacy of injectable treatments through innovative technology, has announced the appointment of Wouter Latour, M.D., as its new Chief Executive Officer (CEO). In addition to his new role, Dr. Latour will also serve on…
Forge Biologics, a key player in Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, has announced the launch of its FUEL™ manufacturing platform. This innovative platform aims to provide developers of adeno-associated virus (AAV) gene therapies with a…
SunLink Health Systems, Inc. (NYSE American: SSY) today reported a loss from continuing operations of $652,000 (or $0.09 per diluted share) for the fourth fiscal quarter ended June 30, 2024, an improvement from the $1,021,000 loss (or $0.15 per diluted…
Odyssey Therapeutics, Inc., a biotechnology firm at the forefront of developing next-generation precision immunomodulators for inflammatory conditions, has announced the establishment of its Scientific Advisory Board (SAB). This board features distinguished experts in immunology and therapeutic development. Stephen Blacklow, M.D.,…
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III REGENCY study of Gazyva®/Gazyvaro® (obinutuzumab) in patients with active lupus nephritis. The study revealed that a higher percentage of patients treated with Gazyva/Gazyvaro in combination…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the Phase 3 KEYFORM-007 trial, which investigated the fixed-dose combination of favezelimab (Merck’s anti-LAG-3 antibody) and pembrolizumab (KEYTRUDA®), did not meet its primary goal of improving…
BioAlberta is excited to announce a new partnership with AxialBridge as its operational and commercialization partner. This collaboration aims to assist Alberta-based biotechnology and MedTech companies in expanding their clinical and research efforts into the United Kingdom. With the launch…
Tennessee Governor Bill Lee, along with Economic and Community Development Commissioner Stuart C. McWhorter and Harrow, Inc. CEO Mark L. Baum, announced today that Harrow is expanding its corporate headquarters in Nashville. Originally founded in San Diego, California, in 2012,…
Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has introduced Medidata Patient Payments, a new solution designed to simplify the process of providing stipends and reimbursements to patients involved in clinical…
